NCT00585507进行中（未招募）2 期
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
- 试验地点
- 10
- 主要终点
- To assess the clinical benefit rate for subjects receiving this dose and schedule of fulvestrant.
研究概览
简要总结
Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. The dose used in studies so far has been well tolerated and may be too low for optimal effectiveness. In this study, a higher dose will be used to see whether an improved outcome will result.
详细描述
- Fulvestrant will be administered by intramuscular injection on day 1, day 15 and day 29 and then every 28 days thereafter.
- Participants will have a physical examination and blood work performed on each treatment date. After teh study treatment has been completed, the physical examinations will be done every three months for the first 2 years, every 6 months for years 2-5, and annually after 5 years.
- Participants may remain on study treatment until disease progression or until they experience serious side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older
- •Histologically confirmed adenocarcinoma of the breast progressing local-regional or metastatic disease that is not considered amenable to curative treatment
- •Evidence of hormone sensitivity of primary or secondary tumor tissue
- •Postmenopausal as defined by criteria listed in protocol
- •May have had adjuvant endocrine therapy if discontinued at least 12 months prior to inclusion. Subjects who have had minimal exposure to adjuvant or first line metastatic endocrine treatment during the 12 months prior to study enrollment can be eligible with overall PI and sponsor permission
- •Prior trastuzumab and biologic therapy is allowed, but must be discontinued more than 2 weeks prior to inclusion
- •Presence of measurable or evaluable, nonmeasurable, disease. Any x-rays and scans for assessment of measurable disease must be performed with 28 days prior to registration
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
排除标准
- •Presence of life-threatening metastatic disease
- •Endocrine therapy the advanced disease setting
- •Systemic chemotherapy, whether as adjuvant therapy or for advanced disease, within previous 4 weeks
- •Trastuzumab or biologic therapy within previous 2 weeks
- •Extensive radiation therapy within the last 2 weeks
- •Prior adjuvant or neoadjuvant treatment with fulvestrant is not allowed
- •Concomitant anticancer treatments
- •Chronic bisphosphonates for hypercalcemia or prevention of bone metastases
- •Subjects receiving long-term anticoagulant therapy with warfarin
- •Estrogen replacement therapy within 6 months of trial entry
- •Previous or current systems malignancy within the past 3 years
- •Treatment with non approved or investigational drug within 2 weeks before study entry
- •Any evidence of severe or uncontrolled systemic disease
- •History of bleeding diathesis
- •Any severe concomitant condition which makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the study protocol
研究组 & 干预措施
single
Experimental
fulvestrant 500mg
干预措施: Fulvestrant (Drug)
结局指标
主要结局
To assess the clinical benefit rate for subjects receiving this dose and schedule of fulvestrant.
次要结局
- Overall objective response rate, time to response, duration of response, duration of clinical benefit, and time to progression.
- Assessment of pharmacokinetics of this dose and schedule of fulvestrant.(4 years)
- Assessment of adverse events(4 years)
研究者
Steven Come
Principal Investigator
Beth Israel Deaconess Medical Center
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor FailureBreast CancerNCT00570921Mara Chambers33
已完成
2 期
First Line Metastatic Breast Cancer Treatment (ESMERALDA)Metastatic Breast CancerNCT01941407ARCAGY/ GINECO GROUP61
已完成
2 期
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast CancerBreast CancerNCT00093002AstraZeneca179
Unknown
2 期
Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast CancerBreast CancerNCT02000193Sun Yat-sen University58
Unknown
1 期
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)Estrogen Receptor-PositiveHER2-NegativeLocally Advanced Breast CancerMetastatic Breast CancerNCT04669587EnhancedBio USA Inc.106